Preclinical assessment of comfort and secure fit of thermobrachytherapy surface applicator (TBSA) on volunteer subjects

Kavitha Arunachalam,¹a Oana I. Craciunescu,² Edward J. Markewitz,³ Paolo F. Maccarini,² Jaime L. Schlorff,³ Paul R. Stauffer²

Department of Engineering Design,¹ Indian Institute of Technology Madras, Tamil Nadu, India; Department of Radiation Oncology,² Duke University, Durham, North Carolina, USA; Bionix Development Corporation,³ Paoli, Pennsylvania, USA

akavitha@iitm.ac.in

Received 14 December, 2011; accepted 2 May, 2012

A thermobrachytherapy surface applicator (TBSA) was developed for simultaneous heat and brachytherapy treatment of chest wall (CW) recurrence of breast cancer. The ability to comfortably secure the applicator over the upper torso relative to the CW target throughout treatment is assessed on volunteers. Male and postmastectomy female volunteers were enrolled to evaluate applicator secure fit to CW. Female subjects with intact breast were also enrolled to assess the ability to treat challenging cases. Magnetic resonance (MR) images of volunteers wearing a TBSA over the upper torso were acquired once every 15 minutes for 90 minutes. Applicator displacement over this time period required for treatment preplanning and delivery was assessed using MR visible markers. Applicator comfort and tolerability were assessed using a questionnaire. Probability estimates of applicator displacements were used to investigate dosimetric impact for the worst-case variation in radiation source-to-skin distance for 5 and 10 mm deep targets spread 17 × 13 cm on a torso phantom. Average and median displacements along lateral and radial directions were less than 1.2 mm over 90 minutes for all volunteers. Maximum lateral and radial displacements were measured to be less than 1 and 1.5 mm, respectively, for all CW volunteers and less than 2 mm for intact breast volunteers, excluding outliers. No complaint of pain or discomfort was reported. Phantom treatment planning for the maximum displacement of 2 mm indicated < 10% increase in skin dose with < 5% loss of homogeneity index (HI) for -2 mm uniform HDR source displacement. For +2 mm uniform displacement, skin dose decreased and HI increased by 20%. The volunteer study demonstrated that such large and uniform displacements should be rare for CW subjects, and the measured variation is expected to be low for multifraction conformal brachytherapy treatment.

PACS numbers: 41.20.Jb, 41.75.-i, 44.

Key words: hyperthermia, conformal microwave array, brachytherapy, chest wall recurrence, breast cancer

I. INTRODUCTION

Randomized phase III clinical trials of superficial tumors extending less than 3 cm in diameter have indicated improved complete response (CR) rates when treated with combined heat and radiation compared to radiation treatment alone.¹⁴ Based on clinical literature, tumor thermal enhancement ratio (TER) has been calculated to be 1.5–1.6 for sequential thermoradiotherapy of advanced and recurrent breast cancer, melanomas, and neck nodes.⁵ Preclinical data have
demonstrated that tumor TER can be increased from 1.5 for sequential treatments to as high as 5.0 when hyperthermia is combined simultaneously with radiation. The benefits of heat-induced radiation effects on cancer and accessibility of superficial tissue to external radiation and hyperthermia make concurrent thermoradiotherapy an appropriate treatment modality for CW recurrence of breast cancer. Clinical feasibility of simultaneous thermoradiotherapy for CW recurrence reported by Myerson et al. provided motivation to develop hyperthermia applicators for simultaneous thermoradiotherapy of large area superficial disease.

A thermobrachytherapy surface applicator (TBSA) has been developed for simultaneous microwave hyperthermia and high dose rate (HDR) brachytherapy treatment of CW recurrence of breast cancer extending 10-15 mm deep from skin surface. Figure 1 shows the rectangular shaped TBSA that accommodates a 915 MHz conformal microwave array (CMA) heat applicator with 18 antennas (3 × 6 array) and 450 cm² treatment area. Superficial hyperthermia is delivered using the CMA through a thin layer of body-conforming water bolus. A pilot study of using CMA applicator for patients with CW recurrence provided excellent controlled heating and good patient tolerance. A parallel array of HDR brachytherapy catheters on the back side of the water bolus is used to deliver conformal radiation dose to the chest wall disease through the microwave array made of thin copper sheet and coupling water layer. Phantom studies of TBSA reported nearly uniform surface cooling capability of the water bolus and very good applicator conformity to a contoured torso phantom. Excellent agreement was obtained between skin dose calculated with the HDR treatment planning system and measured with dosimeters on a tissue equivalent CT phantom.

The purpose of this study is to assess the ability to maintain the relative distance between the HDR brachytherapy catheters and CW separated by a body conforming water bolus to deliver the prescribed radiation dose, and to evaluate applicator comfort during a typical thermobrachytherapy treatment. Thus, a preclinical study was carried out on volunteers to assess the comfort

![Figure 1](image-url)

**Figure 1.** Rectangular shaped TBSA used in the volunteer study: (a) water bolus with thermal mapping catheters on skin contacting side; (b) HDR brachytherapy catheters on the outer side of TBSA; (c) TBSA with MR markers and contrast filled brachytherapy catheters wrapped around a mastectomy volunteer; (d) volunteer with Neoprene over-garment secured over the TBSA.

*Journal of Applied Clinical Medical Physics, Vol. 13, No. 5, 2012*
and secure fit of TBSA over a predefined region of the upper torso. The specific objectives of the volunteer study are: 1) assess ease of placement and time required to treatment preparations; 2) determine patient comfort limitations; 3) quantify lateral movement of TBSA relative to the predefined target; 4) quantify variation in the HDR brachytherapy catheter (source) to skin surface distance; and 5) determine dosimetric impact of the variations determined in step 4.

II. MATERIALS AND METHODS

A. Study protocol
Eligible healthy male and nonpregnant female volunteers, as well as breast cancer patient volunteers with single or double mastectomy, were enrolled on an institute review board (IRB)-approved protocol. Though the intended disease was CW recurrence of breast cancer, female subjects with intact breast were also enrolled to evaluate applicator secure fit for the most challenging cases. Eligibility criteria included 18 years of age or older with the ability to sign consent and the ability to undergo 90 minutes of magnetic resonance imaging (MRI).

During the study, TBSA with degassed water bolus was wrapped securely around the upper torso using elastic support straps and an external elastic Neoprene vest. Since there is no therapeutic intent, the copper-based conformal antenna array and radioactive Ir-192 HDR source were not used in the study. Instead, the 1 cm spaced array of 19 cm long HDR brachytherapy catheters (31 in total) were filled with liquid MR contrast agent (Gadolinium in de-ionized water) to capture the brachytherapy catheters in the MRI scan. MR-visible adhesive markers (MM3005; IZI Medical Products, Owings Mills, MD) fixed on the skin and inner surface of TBSA were distributed along the applicator periphery in three rows with two pairs per row to measure applicator lateral movement with respect to the CW (target).

B. Applicator lateral displacement from CW
Lateral displacement of TBSA with respect to CW was calculated by measuring the distance on each MR image, using the following:

\[ d = \sqrt{(x_{sci} - x_{ac})^2 + (y_{sci} - y_{ac})^2} \]  

where \((x_{sci}, y_{sci}, z_{sci})\) and \((x_{ac}, y_{ac}, z_{ac})\) denote the center of the corresponding \(i^{th}\) marker is not visible. Distance between marker pairs, calculated by

\[ d_i = \{d_i^j\}_{j=1}^N \]  

was calculated for all visible marker pairs in the MR images acquired once every 15 minutes. Distances measured in the 1st scan were used as the baseline measurement to calculate lateral displacement with respect to the CW target.

C. HDR source-to-skin displacement on volunteers
HDR source to skin distance was calculated for each brachytherapy channel \((i)\) by computing the radial distance

\[ \rho_{ij} = \|\rho_{ij}^b - \rho_{ij}^s\|^2 \]  

between the center of the contrast-filled brachytherapy catheter \((\rho_{ij}^b)\) and skin surface \((\rho_{ij}^s)\), both measured with respect to the MR origin \((0, 0, z_j)\) of the \(j^{th}\) axial image. Radial distances were
measured in three axial imaging planes \((j = 1,2,3)\) which, coincided with the middle plane of each row of the \(3 \times 6\) CMA with six antennas per row. Measurements recorded for the same set of M brachytherapy catheters in each imaging plane for the subsequent MR scans were used to track HDR source displacement from the CW. Deviation in the radial distance computed with respect to the first MR scan \(\rho(0)\) was used to quantify HDR catheter displacement from CW target

\[
\Delta \rho(k) = |\rho(0) - \rho(t_j)|
\]

for \(k = 15, 30, 60, 75,\) and 90. The large number of measurements (3M) per scan allowed computation of density distribution and confidence interval for applicator displacement for each volunteer.

D. Dosimetric impact of HDR source-to-skin displacement on phantom

Probabilistic distribution curves estimated from the radial applicator displacement in Section C above were used to assess the dosimetric impact of radial applicator displacement from CW on a homogeneously layered elliptic phantom \((32 \times 20 \times 60\) cm) invariant along the z-axis \((60\) cm). To account for the thickness of the copper heating array, a CMA applicator was used with the TBSA in the phantom study. Due to the significantly low attenuation of photon beam by the thin copper CMA and subsequent absorption of the secondary electron emission by the bolus reported in Taschereau et al. and Craciunescu et al.,(14,23) dose calculations were carried out using BrachyVision (Varian, Palo Alto, CA). Initial plans were generated using CT scans of the elliptic phantom with 8 mm bolus to deliver 100 cGy to cover a patient treatment volume \((PTV)\) defined at 5 mm and 10 mm depths spread \(17 \times 13\) cm across the phantom surface. Dwell times of the HDR source were optimized for 1 cm spacing between the adjacent HDR catheters. Subsequently, plans were generated for uniform variation in bolus thickness (thinning or thickening) based on the density distribution curves estimated in Section C above. Dwell times were kept the same and dose renormalization was not done, in order to assess the dosimetric impact of applicator displacement from the CW. Standard dose parameters, namely coverage index \(V(x)\) or percentage of target volume receiving at least \(x\%\) of dose (where \(x = 100, 130, 140\)), dose received by 100\% of the target \(D_{100}\), homogeneity index \((HI = V_{100} - V_{140})\), skin dose \((cGy)\), and skin gradient \((cGy/mm)\) were calculated and compared between an unperturbed \((8\) mm constant thickness bolus) and the perturbed configurations (uniformly thicker and thinner bolus with respect to \(8\) mm bolus).

E. Comfort assessment

The ease of TBSA placement and time required to complete volunteer preparations for heat/HDR brachytherapy treatment were documented for each subject. A questionnaire filled out by the volunteers at the end of the study was used to assess TBSA comfort and tolerance during the 90 minute period, which corresponds to 150\% of the typical hyperthermia treatment time. A numeric scoring sheet was used to convert the qualitative metrics of comfort experienced by the volunteers.

III. RESULTS

A. Study population and applicator conformity

Table 1 lists the subjects enrolled in the volunteer study. Figure 1 shows the typical placement of the rectangular TBSA on a volunteer. The applicator was positioned with considerable ease and the average time to prepare the subject for scanning was 15 minutes. MR images of
volunteers in Fig. 2 show excellent applicator conformity to the CW. MR markers with bright signal intensity appearing in all imaging planes were used for analysis.

### Table 1. Volunteers enrolled in the preclinical volunteer study.

| Volunteer | Gender | Age | Remarks | Imaging Region |
|-----------|--------|-----|---------|----------------|
| 1         | Male   | 25  | None    | Chest wall     |
| 2         | Female | 40  | Single mastectomy | Chest wall |
| 3         | Male   | 24  | None    | Chest wall     |
| 4         | Female | 24  | Healthy, intact breast | Intact breast |
| 5         | Female | 30  | Double mastectomy | Chest wall |
| 6         | Female | 30  | Intact breast, lumpectomy | Intact breast |
| 7         | Female | 56  | Single mastectomy | Chest wall |
| 8         | Female | 57  | Single mastectomy | Chest wall |

**Fig. 2.** MR images of volunteer CW: (a)–(c) axial images of mastectomy and healthy volunteers with excellent conformity of TBSA to CW; MR images indicate MR visible marker pairs on the skin and TBSA that were used to assess applicator lateral displacement. The bright dots above the water bolus from the liquid MR contrast filled inside the parallel array of brachytherapy catheter channels were used to assess radial displacement of HDR catheters from the CW surface.

### B. Applicator lateral displacement on volunteers

Figure 3(a) shows the average and maximum values of the lateral applicator displacements ($|d_c(0) - d_c(30)|$) measured in this study. These measurements correspond to the lateral displacement that can be expected at the start of thermobrachytherapy (i.e., 30 minutes after the baseline scan is obtained for HDR brachytherapy planning). Figure 3(b) gives the displacement ($|d_c(30) - d_c\text{ (end)}|$) that can be expected during a 60 minute thermobrachytherapy treatment. Figure 3(c) shows lateral displacement $|d_c(0) - d_c\text{ (end)}|$, at the end of study measured with respect to the baseline scan. Figure 3 demonstrates that the TBSA remained in position throughout the study with less than 1 mm lateral movement from the skin surface for the CW volunteers (male & postmastectomy subjects) compared to the volunteer group with intact breast (subjects 4 and 6).
The number of brachytherapy channels (M) used to measure HDR source-to-skin displacement ranged from 16 to 30, depending on catheter visibility in the three imaging planes (mean = 22, median = 21). Figure 4(a) shows the statistics computed using the 3M radial applicator displacement data (\( \left| \rho(0) - \rho(30) \right| \)) 30 minutes after the start of the study. Figure 4(b) shows the displacement measured at the end of study with respect to the baseline scan. The median displacement indicated by horizontal line inside the box plot is less than 1 mm for both volunteer groups (CW, intact breast) and time instants (30, 90 minutes). It can be observed that the span of the radial displacement data is larger for intact breast volunteers compared to the CW group. Similar observations were made for \( \left| \rho(30) - \rho(\text{end}) \right| \) (data not shown).

Figure 5(a) shows the probability distribution function estimated for the radial applicator displacement, \( \left| \rho(0) - \rho(30) \right| \) for the individual volunteer. The skewed distribution curves observed for all volunteers indicate a low variation in the applicator displacement from CW. It should also be noted that the outliers, which correspond to the tail end of the distribution, exceed beyond 2 mm. The 95% confidence interval for the mean value of the radial displacement \( \left| \rho(0) - \rho(30) \right| \) in Fig. 5(b) indicates a tighter span (\( \leq 5 \) mm) about the mean for all volunteers. Similar performance was observed for \( \left| \rho(30) - \rho(\text{end}) \right| \) and \( \left| \rho(0) - \rho(\text{end}) \right| \) (data not shown).
Note: Box plot parameters: box limits: 25th and 75th percentiles of displacement data, horizontal line: median displacement; whiskers: minimum and maximum displacements; x markers: outliers.

**Fig. 4.** Radial displacements of HDR brachytherapy catheters from the CW surface: (a) applicator displacement 30 minutes after baseline scan (i.e., displacement at start of thermobrachytherapy treatment); (b) displacement measured between the first and last scans.

**Fig. 5.** Density distribution curves (a) of the 3M HDR catheter-CW displacement measurements $|\rho(0) - \rho(30)|$ which correspond to the relative shift in position of TBSA catheters at the start of thermobrachytherapy treatment, 30 minutes after the baseline data was obtained for HDR pretreatment planning. 95% confidence interval (b) (solid line) for the mean (cross marking) displacement of $|\rho(0) - \rho(30)|$. Density distributions and the estimated confidence intervals indicate very small variation in radial applicator displacement.
D. Dosimetric impact of HDR source-to-skin displacement on phantom

A 2 mm displacement observed at the tail end of the distribution functions in Fig. 5(a) was used to compare the dosimetric computed for uniform perturbation in bolus thickness from the average thickness (8 mm). Figure 6 shows the transverse isodose lines for a prescription of 100 cGy to 10 mm deep target in case of unperturbed water bolus (8 mm) and bolus thickness variation of ± 2 mm. Figure 7 shows the dose volume histogram (DVH) for two targets when displaced by ± 2 mm uniformly across the treatment planning surface. The dose metrics derived from Figs. 6 and 7 are summarized in Table 2. This table also includes skin dose and skin dose gradient for ± 1 mm displacement, as we determined that the median as well as the mean HDR source-to-skin displacement is less than 1 mm (see Figs. 4 and 5(b)). Notably though, the V(x), D100 and HI metrics were not calculated for ± 1 mm, as the treatment planning software lacked the ability to distinguish contours down to one mm resolution.

For negative displacements, the most relevant metric to look at is skin dose. The data in Table 2 infer that differences in skin dose are < 5% for 1 mm and < 10% for 2 mm displacements with only modest change in skin gradient. The V(100) and D100 improve with a negative displacement, and changes in the hot spots are minimal but, as expected, are larger for the deeper target. For positive displacement, meaning the water bolus becomes thicker by 1–2 mm, skin dose is no longer an overdose concern, since it decreases. The dosimetric metrics of importance are the coverage indexes. With a 2 mm uniform increase in water bolus thickness across the treatment surface, the HI varies by 20%, stemming from the large variation in V100.

Fig. 6. Transverse isodose distributions for a prescription of 100 cGy to 10 mm deep target in the case of undisturbed bolus (8 mm) and bolus thickness variation of ± 2 mm.
Fig. 7. Dose volume histograms for 5 mm (top) and 10 mm (bottom) deep targets calculated for the nominal 8 mm thick water bolus (solid lines) and for thicker (10 mm, dashed lines) and thinner (6 mm, dotted-dashed lines) water bolus.

Table 2. Summary of dose metrics for 5 mm and 10 mm deep targets and ±2 mm variation in bolus thickness.

| Dose Metrics          | Target 5 mm | 0 mm | -1/-2 mm | +1/+2 mm | Target 10 mm | 0 mm | -1/-2 mm | +1/+2 mm |
|-----------------------|-------------|------|----------|----------|--------------|------|----------|----------|
| Skin dose [cGy]       | 123.4       | 128.7/134.0 | 119.2/115.5 | 132.0    | 136.7/140.8 | 128.5/125.0 |
| Skin gradient [cGy/mm]| 4.2         | 4.2/5.3  | 4.2/3.6  | 3.5      | 3.5/4.1  | 3.5/3.2  |
| HI (V100-V140) [%]    | 98.4        | 97.9    | 76.8     | 96.0     | 91.9     | 85.3     |
| V(100) [%]            | 98.7        | 100.0   | 76.8     | 98.3     | 100.0    | 85.7     |
| V(130) [%]            | 1.9         | 7.3     | 0.22     | 9.8      | 23.8     | 2.6      |
| V(140) [%]            | 0.3         | 2.11    | 0.0      | 2.3      | 8.1      | 0.4      |
| D(100) [cGy]          | 98.4        | 101.1   | 93.9     | 96.4     | 99.2     | 93.4     |

Note: Coverage index, V(x) is the percentage of target volume receiving x% of dose or more (x=100, 130, 140), HI is the homogeneity index and D(100) is the dose received by 100% of target. V(x), D(100) and HI were not calculated for ±1 mm displacement as the treatment planning software lacks this resolution in defining planning target volumes.
Figure 8 summarizes the comfort questionnaire filled out by volunteers at the end of the study. (Numerical scores of applicator comfort were not available for the 1st volunteer as the questionnaire was under revision. However, oral feedback from this healthy male volunteer indicated comfortable applicator placement.) The applicator setup was comfortable and well-tolerated by all volunteers, and the comfort level did not change much during the 90 minute study. The comfort questionnaire revealed a small number of minor complaints such as feeling a contact point under the arm or over the shoulder. No complaints of pain, breathing difficulty or significant discomfort were recorded by any of the subjects.

**IV. DISCUSSION**

This effort describes the testing of the comfort and secure fit of a thermobrachytherapy surface applicator developed for simultaneous heat and HDR brachytherapy treatment of CW recurrence of breast cancer in postmastectomy patients with laterally diffuse disease extending < 15 mm from the skin surface. The advantages of HDR brachytherapy include: accuracy and precision of tumor specific radiation dose delivery, fewer side effects, excellent coverage of irregularly shaped target disease, and a shorter course of treatments compared to standard fractionated external beam radiotherapy. The safe use of customized surface molds for HDR brachytherapy treatment of superficial disease has been reported for chest wall recurrence in pre-irradiated postmastectomy patients, skin carcinoma, cancers of the scalp, head and neck cancer, and scar boost radiation after breast reconstruction. The body conforming water bolus of the TBSA with a thin layer of uniform thickness filter foam acts as a surface mold for HDR brachytherapy. During HDR brachytherapy, it is vital to maintain the preplanned distance between the brachytherapy catheters and CW surface. This volunteer study was initiated to measure the spatial variation in the distance between HDR brachytherapy catheters and CW...
surface over a 90 minute period. The 90 minute study duration includes 30 minutes for initial scanning and HDR pretreatment planning, and 60 minutes for thermobrachytherapy treatment. Study was conducted in the absence of the copper heating antenna array and HDR source to assess applicator comfort and secure fit. Another reason for not including the copper heating array was because of the electromagnetic (EM) interference provided by the CMA applicator to the MR pickup coils.

Excellent applicator conformity to the torso was observed for all CW volunteers (Fig. 2), which is the intended tissue target for TBSA. For the chest wall volunteers, the sequential scans demonstrated less than 1.0 mm maximum (0.78 mm median) movement laterally across the target surface. The maximum lateral displacement was measured as 2.7 and 0.75 mm for 4th and 6th intact breast volunteers, respectively (Fig. 3). Excluding the outlier measurements reduced the maximum lateral displacement to less than 2 mm for the 4th volunteer. The mean lateral applicator displacement was well below 1 mm for both intact breast volunteers, excluding the outlier measurement of 4th subject. Dosimetric impact of this 1 mm mean lateral applicator displacement from CW target was not simulated since a 1 mm change in target contour could be resolved by the treatment planning software.

The maximum HDR source-to-skin displacement was measured to be less than 1.5 mm for the CW volunteers (Fig. 4). The maximum radial displacements measured for the intact breast group were 3.35 and 1.3 mm for volunteer #4 and #6, respectively (Fig. 4). The largest displacement of 3.35 mm noted for the 4th volunteer is a measurement outlier, as seen in Fig. 4(b). Exclusion of the outlier measurements yielded less than 2 mm variation in HDR source-to-skin displacement for the intact breast volunteer group. The mean and median radial displacements computed for the intact breast group was less than 1 mm (see Figs. 4 and 5) similar to the CW group. The larger variation in applicator displacement measured for the intact breast group compared to the CW group is due to practical difficulties in fitting the applicator to the intact breast. Displacement measurements in Figs. 3 to 5 obtained from the sequential MR images indicate that the TBSA can be secured to the CW with low variation (< 2 mm) during an hour long thermobrachytherapy of the CW disease.

Dosimetrics summarized in Table 2 for an unperturbed (8 mm bolus) and perturbed treatment setups (10 and 6 mm bolus) calculated for ± 2 mm variation based on data distribution in Fig. 5(a) indicated about 10% increase in skin overdose for the 10 mm deep target with less than 3% variation in HI. However, it should be noted that the skin is also a part of the CW disease and variation in skin dose is less than 10% for a uniform decrease in bolus thickness across the treatment surface. For positive displacement, the variation in HI index is relatively larger (as much as 20%) due to the increase in the depth of the target location from the HDR source. Dose delivered to the skin is relatively lower for positive displacement due to radiation attenuation inside the thicker bolus. It should be noted that the dosimetric in Table 2 provides the worst-case scenarios that can result due to change in bolus volume between treatments in a multifractionated thermobrachytherapy treatment. In reality, the bolus volume is maintained the same between and during treatments to avoid perturbations in EM power deposition inside tissue. A detailed brachytherapy treatment planning of this volunteer data is expected to provide better dosimetric than the phantom study and will determine the clinical acceptability of the applicator displacement measurements.

The overall comfort rating of the setup varied between tolerable and surprisingly comfortable for the postmastectomy volunteers, as seen in Fig. 8. Comfort level remained essentially the same for the duration of study for all volunteers, and none experienced pain or breathing difficulty. Based on prior clinical experience with the CMA heat applicator, sweating and minor discomfort from the hyperthermia treatment are expected to remain the most significant factors in patient comfort during thermobrachytherapy. That expectation was confirmed in the results of this study. In clinical use of the TBSA, the anticipated causes for applicator movement relative to chest wall target will consist of patient movements on and off the CT table for radiation planning scans, patient transfer to the hyperthermia/brachytherapy delivery bed, and
minor patient movements during the 60 min treatment interval. As tested in this study, such applicator movements could be minimized during treatment using MR visible marker pairs on skin and applicator, and securing the TBSA with elastic straps and an overlying elastic vest.

V. CONCLUSIONS

A quantitative assessment of the comfort and secure fit of a thermobrachytherapy surface applicator (TBSA) was carried out on volunteer subjects for 90 min to simulate a complete procedure involving pretreatment scans followed by time sufficient for planning and delivery of simultaneous heat and radiation to a chest wall target. Applicator displacement relative to the chest wall target was assessed with MR scans of the torso of each volunteer at 15 min intervals for 90 min, with realistic patient movement allowed between scans. As expected, higher displacement was measured for volunteers with intact breast compared to those with chest wall target. This preclinical study confirms that simultaneous thermobrachytherapy is feasible with an easy-to-use TBSA that provides uniform treatment of large area CW disease while remaining comfortable for the patient. The outcome of this volunteer study strongly supports future clinical testing of TBSA as a means to enhance the synergism of heat and radiation in diffuse superficial disease.

ACKNOWLEDGMENTS

This research was supported by NIH grants RO1-CA70761, P01-CA-042745, and R44-CA104061 with Bionix Development Corporation. The authors would like to thank hyperthermia treatment technologist Wendy Covington, and MR technician Kevin Kelly of the Department of Radiation Oncology, Duke University Medical Center, for their assistance with the volunteer study.

REFERENCES

1. Jones E, Oleson J, Prosnitz L, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005;23(13):3079–85.
2. Perez CA, Pajak T, Emami B, Hornback NB, Tuchong L, Rubin P. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol. 1991;14(2):133–41.
3. Sherar M, Liu FF, Pintilie M, et al. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial. Int J Radiat Oncol Biol Phys. 1997;39(2):371–80.
4. Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. Int J Radiat Oncol Biol Phys. 1996;35(4):731–44.
5. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys. 1989;16(3):535–49.
6. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980;6(11):1507–17.
7. Myerson RJ, Straube WL, Moros EG, et al. Simultaneous superficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to treatment. Int J Hyperthermia. 1999;15(4):251–66.
8. Gelvich EA, Klimanov VA, Kramer-Ageev EA, Mazokhin VN. Computational evaluation of changes in ionizing radiation dose distribution in tissues caused by EM applicators when external radiation and hyperthermia act simultaneously. Int J Hyperthermia. 2006;22(4):343–52.
9. Moros EG, Peñagaricano J, Novák P, Straube WL, Myerson RJ. Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer. Int J Hyperthermia. 2010;26(7):699–709.
10. Novák P, Moros EG, Straube WL, Myerson RJ. SURLAS: a new clinical grade ultrasound system for sequential or concomitant thermoradiotherapy of superficial tumors: applicator description. Med Phys. 2005;32(1):230–40.
11. Stauffer P, Schlorf J, Taschereau R, et al. Combination applicator for simultaneous heat and radiation. Conf Proc IEEE Eng Med Biol Soc. 2004;4:2514–17.
12. Straube WL, Moros EG, Low DA, Klein EE, Wiltcut VM, Myerson RJ. An ultrasound system for simultaneous ultrasound hyperthermia and photon beam irradiation. Int J Radiat Oncol Biol Phys. 1996;36(5):1189–1200.
13. Juang T, Stauffer PR, Neuman DG, Schlortf JL. Multilayer conformal applicator for microwave heating and brachytherapy treatment of superficial tissue disease. Int J Hyperthermia. 2006;22(7):527–44.
14. Taschereau R, Stauffer PR, Hsu IC, Schlortf JL, Milligan AJ, Pouliot J. Radiation dosimetry of a conformal heat-brachytherapy applicator. Technol Cancer Res Treat. 2004;3(4):347–58.
15. Rossetto F and Stauffer PR. Theoretical characterization of dual concentric conductor microwave array applicators for hyperthermia at 433 MHz. Int J Hyperthermia. 2001;17(3):258–70.
16. Maccarini P, Arunachalam K, Martins C, Stauffer P. Size reduction and radiation pattern shaping of conformal microwave array hyperthermia applicators using multi-fed DCC slot antennas. Conf Proc of SPIE. 2009;718107:1-9.
17. Maccarini PF, Rolfsnes HO, Johnson J, Neuman DG, Jacobsen S, Stauffer PR. Electromagnetic optimization of dual mode antennas for radiometry controlled heating of superficial tissue. Conf Proc of SPIE. 2005;5698:71–78.
18. Stauffer P, Maccarini P, Juang T, et al. Progress on conformal microwave array applicators for heating chestwall disease. Conf Proc of SPIE. 2007;64400E:1–13.
19. Stauffer PR. Thermal therapy techniques for skin and superficial tissue disease. In: Ryan TP, editor. A critical review, matching the energy source to the clinical need. Bellingham, WA: SPIE Optical Engineering Press; 2000. p. 327–67.
20. Arunachalam K, Maccarini P, Schlortf J, Birkeland Y, Jacobsen S, Stauffer PR. Design of a water coupling bolus with improved flow distribution for multidetement superficial hyperthermia applicators. Int J Hyperthermia. 2009;25(7):554–65.
21. Arunachalam K, Craciunescu OI, Maccarini P, Schlortf J, Markowitz E, Stauffer PR. Progress on thermo-brachytherapy surface applicator for superficial tissue disease. Conf Proc of SPIE. 2009;71811OC-1-12.
22. Arunachalam K, Maccarini PF, Craciunescu OI, Schlortf JL, Stauffer PR. Thermal characteristics of thermobrachytherapy surface applicators (TBSA) for treating chestwall recurrence. Phys Med Biol. 2010;55(7):1949–69.
23. Craciunescu OI, Arunachalam K, Steffey BA, Maccarini P, Schlortf J, Stauffer PR. Dosimetric characterization of the thermobrachytherapy surface applicator. Presented at the American Brachytherapy Society Annual Meeting 2009, Toronto, Canada, May 31 - June 2. Brachytherapy. 2009;8(2):157–58.
24. Stauffer PR, Maccarini P, Arunachalam K, et al. Conformal microwave array (CMA) applicators for hyperthermia of diffuse chestwall recurrence. Int J Hyperthermia. 2010;26(7):686–98.
25. Hoskin P and Coyle C, editors. Radiotherapy in practice – brachytherapy. New York, NY: Oxford University Press; 2005.
26. Sharma SC, Negi PS, Singh DP, Munjal RK, Goyal D, Patel FD. High dose rate surface mould brachytherapy for superficial localised chest wall recurrences in postmastectomy carcinoma breast patients. J Clin Radiother Oncol. 1997;12(1-2):1–6.
27. Guix B, Finestres F, Tello J, et al. Treatment Of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys. 2000;47(1):95–102.
28. Nakamura R, Harada S, Obara T, et al. Iridium-192 brachytherapy for hemorrhagic angiosarcoma of the scalp: a case report. Japan J Clin Oncol. 2003;33(4):198–201.
29. Semrau S, Kunz M, Baggesen K, et al. Successful treatment of field cancerization of the scalp by surface mould brachytherapy. Br J Dermatology. 2008;159(3):733–72.
30. Chaudhary AJ, Bhalavat RL, Sharma V, Tamane CJ, Sequeira BE. Surface mould brachytherapy using 192 Iridium in head and neck cancers. J Clin Radiother Oncol. 2997;13(1-2):7–14.
31. Stewart AJ, O’Farrell DA, Bellon JR, et al. CT computer-optimized high-dose-rate brachytherapy with surface applicator technique for scar boost radiation after breast reconstruction surgery. Brachytherapy. 2005;4(3):224–29.